Silent No More: Protesters Demand Consumer Voice at Tobacco Control Summit
DUBLIN, June 24, 2025 (GLOBE NEWSWIRE) -- On the opening day of the World Conference on Tobacco Control (WCTC) in Dublin, the World Vapers' Alliance staged a silent protest outside the venue, visually highlighting the exclusion of consumers from global tobacco and nicotine policy debates. Demonstrators with their mouths taped symbolised the ongoing marginalisation of those most affected by regulatory decisions.
The protest is part of the 'Voices Unheard—Consumers Matter!' campaign, launched as delegates gathered inside to discuss the future of tobacco control without meaningful input from the consumers who are most impacted by these policies. This exclusion is especially concerning with COP11 in Geneva approaching and the World Health Organization pushing for bans on flavoured nicotine products—a move that would deny adults safer alternatives.
Michael Landl, Director of the World Vapers' Alliance, warned that outdated, ideologically driven policies, often influenced by powerful interests like Michael Bloomberg, threaten to reverse progress in reducing smoking rates. 'Safer nicotine alternatives have the potential to save millions of lives, but only if they are supported by sensible, evidence-based regulation. We cannot afford to let ideology stand in the way of real progress,' Landl said.
The campaign comes at a time when the World Health Organization (WHO) is pushing for sweeping bans on flavoured nicotine products, including e-cigarettes and nicotine pouches. Such measures would remove vital tools from adults seeking to quit smoking and could drive many back to combustible tobacco.
Alberto Gómez Hernández, Policy and Advocacy Manager for the WVA, stressed the importance of listening to consumers. 'Instead of banning flavours and safer alternatives, we need policies that protect both youth and adult smokers who want to quit smoking,' he explained.
The protest underscores the urgent need for genuine consumer inclusion and evidence-based harm reduction as the world prepares for COP11.
For media enquiries and high-resolution images, please contact: Michael Landl info@worldvapersalliance.comWORLD VAPERS' ALLIANCE INC 18117 BISCAYNE BLVD PMB 60190 MIAMI, FL 33160
High-quality pictures of the protest can be found here.
More information about flavour bans: https://worldvapersalliance.com/wp-content/uploads/2025/06/Briefing-WHO-Flavour-Ban.pdf
More about the WVA's demands: https://worldvapersalliance.com/wp-content/uploads/2025/03/Rethinking-Tobacco-control-Report.pdf
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5d4efecb-c0f8-4b11-b8e1-a6ca20c5548a
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
9 minutes ago
- Medscape
Graft Failure Risk Rises in Paediatric Kidney Retransplants
TOPLINE: In paediatric kidney transplant recipients, the risk for graft failure increased with each subsequent transplantation. After the second transplant, older donor age, transplantation from a deceased donor, shorter survival of the primary graft in non-sensitised recipients, higher panel-reactive antibody (PRA) levels, and an increasing number of human leucocyte antigen DR (HLA-DR) mismatches predicted a higher risk for graft failure. METHODOLOGY: Researchers analysed data from a European registry to determine the incidence and risk factors for graft failure and death after repeat kidney transplantation in paediatric recipients across Eurotransplant countries. They included 4527 primary paediatric kidney transplant recipients (median age, 11 years; 41% girls), of whom 1155 underwent a second, 259 a third, and 41 a fourth kidney transplantation. The median follow-up duration for the first, second, third, and fourth kidney transplantation was 8.83, 6.67, 5.75, and 5.58 years, respectively. The probability of graft failure (the need for dialysis or retransplantation) and death with a functioning graft was analysed in kidney transplantation recipients. Patient data collection included recipient sex and age; country; transplantation dates; PRA levels; primary kidney disease; graft failure dates; donor source, age, and sex; and the number of HLA mismatches. TAKEAWAY: The risk for graft failure increased with each subsequent kidney transplant, with 5-year rates of 15% after the first, 24% after the second, 30% after the third, and 40% after the fourth transplant. The risk for graft failure or death with a functioning graft was the highest in the first month after primary kidney transplantation and increased even further after each subsequent transplantation. After the second transplant, transplantation from deceased donors, older donor and recipient age, shorter survival of the first graft in non-sensitised recipients, higher PRA levels (1%-100%), and an increasing number of HLA-DR mismatches were associated with an increased probability of graft failure and death with a functioning graft. Transplants performed in more recent years were also associated with better survival outcomes. IN PRACTICE: "Each subsequent kidney transplantation in pediatric recipients carried a higher risk of GF [graft failure], particularly in the first months post-transplant. After the second transplantation, older calendar year of KTx [kidney transplantation], deceased donor (DD), older donor and recipient age, and increasing HLA-DR mismatches were associated with a higher predicted GF and death with functioning graft," the authors wrote. "In DD kidney allocation schemes, 2 HLA-DR mismatches should be avoided," they added. SOURCE: This study was led by Ferran Coens, Ghent University Hospital, Ghent, Belgium. It was published online on August 07, 2025, in Pediatric Nephrology. LIMITATIONS: This study had substantial missing data for HLA mismatches in living donor transplants, limiting the analysis of HLA mismatches to deceased donor kidney transplant recipients alone. Additionally, the analysis did not adjust for certain relevant peri- and post-transplant predictors of graft failure, such as cold and warm ischaemia time, socioeconomic status, and allograft rejection. DISCLOSURES: The registry involved in this study received funding through a grant from the Dietmar Hopp Stiftung, the European Society for Paediatric Nephrology, the German Society for Pediatric Nephrology, and other sources. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
9 minutes ago
- Medscape
Drug Combinations for CVDs Tied to Bullous Pemphigoid Risk
TOPLINE: A case-control study revealed that combinations of drugs for cardiovascular diseases and hypertension were frequently prescribed before a diagnosis of bullous pemphigoid (BP), but the risk associated with combinations did not exceed that associated with individual agents. The most common drug combinations included angiotensin-converting enzyme (ACE) inhibitors with statins and antiplatelets with statins. METHODOLOGY: Researchers conducted a nested case-control study using healthcare records from the Clinical Practice Research Datalink between 1998 and 2021 and analysed 16,844 BP cases and 79,493 age- and sex-matched control individuals having no BP diagnosis at the index date (the first date a BP diagnosis code was recorded). Association rule mining (ARM) identified the 10 most common drug class or active substance pairs prescribed to cases or control individuals on the same day and within 6 months before the index date. In the sensitivity analysis, researchers identified medication pairs prescribed within 30 days of each other and during the 6 months preceding the index date. Researchers quantified how often two drugs are co-prescribed compared with their independent prescribing by calculating a lift. They then derived the fold change (FC) as the ratio of a lift in cases vs control individuals. The analysis included multivariable conditional logistic regression to estimate the risk for BP following drug combinations and their constituent drugs. TAKEAWAY: The most frequent drug combinations associated with an increased risk for BP were ACE inhibitors-statins (FC of the lifts in the main analysis vs sensitivity analysis: 1.31 vs 1.18), antiplatelets-statins (1.23 vs 1.11), proton pump inhibitors (PPI)-antiplatelets (1.22 vs 1.14), PPI-statins (1.22 vs 1.14), and ACE inhibitors-antiplatelets (1.20 vs 1.09). For drug substances, combinations with a greater lift in BP cases were simvastatin-ramipril (FC, 1.30), simvastatin-aspirin (FC, 1.21), and ramipril-aspirin (FC, 1.19). After adjusting for BP-associated drugs, the Charlson Comorbidity Index, and relevant confounders, the increased risk remained significant for these drug class combinations: antiplatelets-statins (odds ratio [OR], 1.20), ACE inhibitors-statins (OR, 1.16), PPI-statins (OR, 1.22), ACE inhibitors-antiplatelets (OR, 1.26), and PPI-antiplatelets (OR, 1.43; P < .001 for all). The risk for BP associated with these frequently prescribed drug combinations was lower than the risk linked to each constituent drug at both class and substance levels. In both main and sensitivity analyses, patients who developed BP were more likely than control individuals to have received combinations of cardiovascular or antihypertensive drugs before diagnosis. IN PRACTICE: "The ARM algorithm exploratory analysis identified the most commonly prescribed drug combinations prior to BP. Logistic regression confirmed drug combinations for CVDs [cardiovascular diseases] or hypertension associated with increased BP risk," the authors wrote. "The increased BP risk following reported combinations was modest and was not greater than their constituent drugs. Given that the number of patients with BP is low, we do not suggest avoiding the reported drugs but instead being on the lookout for any skin reactions following treatments for CVDs or hypertension," they concluded. SOURCE: This study was led by Mikolaj Swiderski, University of Nottingham, Nottingham, England. It was published online on August 06, 2025, in Clinical and Experimental Dermatology. LIMITATIONS: The ARM algorithm considered only the frequency of prescriptions to obtain drug combinations. Additionally, the algorithm demonstrated limited clinical value, linking only half of the inferred drug class combinations with BP and failing to capture the sequence or precise timing of prescriptions. It also lacked dosage and treatment duration data, and as an exploratory tool, ARM could not establish causal relationships between drug exposures and the risk for BP. DISCLOSURES: This research was supported by the National Institute for Health and Care Research grant via the Research for Patient Benefit Programme. Swiderski reported receiving salary funding from this grant. Another author reported receiving salary funding from King's College London, University of Nottingham, and the National Institute for Health and Care Research East Midlands scholarship scheme. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
CNET
2 hours ago
- CNET
Your Smartwatch's Sleep Tracker May Be Sleeping on the Job
If sleep is important to you -- and it should be -- you might want to think twice before you put a lot of stock in the latest stress charts from your fitness wearable. A recent study from the Netherlands' Leiden University, published in the Journal of Psychopathology and Clinical Science, has found that when smartwatches and similar devices record readings on stress, fatigue or sleep, they're frequently getting it wrong. Researchers studied 800 young adults using the same Garmin Vivosmart 4 smartwatch model. They compared the data the smartwatches produced with the reports that the users created four times per day about how sleepy or stressed they were feeling. Lead author and associate professor Eiko Fried said the correlation between the wearable data and the user-created data was "basically zero." A representative for Garmin did not immediately respond to a request for comment. Stressed or sex? Your watch doesn't know So why do wearables like fitness smartwatches get it so wrong? Their sensors are fairly limited in what they can do. Watches like these need to be worn correctly at all times (a loose or tight watch may give poor readings, for example), and they typically use basic information like pulse rate and movement to make guesses about health. Those guesses don't always reflect real-world scenarios. A wearable may identify high stress when the real cause of the change was a workout, excitement over good news or sex. There are so many potential alternatives to stress or fatigue that the watches in the study never really got it right -- and the devices sometimes guessed the complete opposite emotional state from what users recorded. The Dutch study did note that Garmin's Body Battery readings, which specifically measure physical fatigue, were more reliable than stress indicators, but still inaccurate. And sleep sensing performed the best of them all, with Garmin watches showing a two-thirds chance of noting the differences between a good night's sleep and a bad one. It's also worth noting that smartwatch sensors can become more accurate as technology improves. It would be interesting to run a similar study with the newer Garmin Vivosmart 5 to see if anything has improved, as well as see if other models like the latest versions of the Apple Watch have similar accuracy results.
